News

Studies, advances, and authorizations continue in this paramount area within infectious disease.

The CDC director endorsed the vote, and vaccines could be available to this young pediatric population by later this week.

This past week has been extremely busy in infectious disease with a lot of vaccine news that could impact young children. In addition, GSK reported on its phase 3 study on its RSV vaccine for seniors.

Using confirmed monkeypox cases in the Netherlands, investigators estimated the average time from infection to symptom onset was 8.5 days.

Following VRBPAC recommendations earlier this week, both the Pfizer-BioNTech and Moderna COVID-19 vaccines were FDA-authorized for children as young as 6 months.

Government agencies and researchers continue to monitor the potentially troubling trend.

At separate press conferences, the CDC and WHO indicate that containing monkeypox will depend on testing, tracing, and currently available vaccines.

Out of 102 monoclonal antibodies tested, only Cv2.1169 and Cv2.3194 cross-neutralized all variants of concern, including Omicron BA.1 and BA.2 subvariants.

The South African National Department of Health has updated their HIV regimen recommendations for patients aged older than 10 years and more than 35 kg.

Today, the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend both the Moderna and Pfizer-BioNTech COVID-19 vaccines for children as young as 6 months old.

High vaccination rates at Cornell University prevented severe disease during the Omicron surge of the COVID-19 pandemic but didn’t stop the rapid spread of the virus, even with comprehensive public health measures.

The first report from WHO Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) concedes SARS-CoV-2 source remains a mystery.

Green Pharmaceuticals Inc. issued a voluntary recall of their SnoreStop NasoSpray after FDA testing found the product contaminated with the microbe Providencia rettgeri.

Aethlon Medical’s proprietary Hemopurifier is being studied to treat COVID-19, and they recently reported results.

The CDC recently compiled surveillance data showing the span and prevalence of 7 major pathogens commonly carried by blacklegged ticks.

The start of Men’s Health Week offers an opportunity for men to get screened for a variety of health issues and be proactive with their health including those who might be at risk of HIV and may benefit from PrEP.

“It’s time to ensure widespread availability by promoting access to safe, effective, and sustainably priced medications, rather than providing incentives to prescribe higher-cost alternatives,” the authors said.

Rather than developing vaccines for each new variant, some officials are pushing to follow the flu vaccine model, with annual vaccination.

People exposed to a family member recently hospitalized with C difficile infection were 73% more likely to contract CDI themselves.

Joined by Steven Wolfe, DO, MPH, and Stuart A Fisk, CRNP, of the Allegheny Health Network, we discuss the populations most at risk of HIV infection, as well as advice for making healthcare spaces more inclusive and accessible for LGBTQ+ people.

Data results from its phase 3 trial showed it was statistically significant and the company plans to follow-up with regulatory bodies later this year.

Tecovirimat (Tpoxx) is an antiviral agent that is already indicated for another orthopoxvirus, smallpox. And studies are ongoing to see if it has potential efficacy in treating monkeypox.

Merck’s antiviral drug molnupiravir may benefit nonhospitalized patients with mild or moderate COVID-19, according to a secondary analysis of phase 3 clinical trial data.

Immunization against COVID-19 benefits pregnant women as well as their offspring.

AstraZeneca’s Evusheld, dual injections of tixagevimab and cilgavimab, reduced the risk of severe or fatal COVID-19 disease by 50%. When administered within 3 days of symptom onset, Evusheld had an 88% risk reduction.

Rebound in COVID-19 symptoms, retesting positive for SARS-CoV-2, and recurring infectivity after Paxlovid treatment mars "test and treat."

A recent study in the United Kingdom suggests that more research into the possible benefits of antiviral drug tecovirimat for treating monkeypox may be warranted after showing positive results in one patient.